INTENSIFY - Schizophrenia
Research type
Research Study
Full title
A randomised, controlled trial to investigate the effect of a six week intensified pharmacological treatment for schizophrenia compared to treatment as usual in subjects who had a first-time treatment failure on their first-line treatment.
IRAS ID
1008551
Contact name
Inge Winter
Contact email
Sponsor organisation
University Medical Center Utrecht
Clinicaltrials.gov Identifier
Research summary
When people with a psychotic disorders are diagnosed, treatment is initiated and usually an antipsychotic medication is started. Beforehand it is unknown if the medication will reduce symptoms and what side effects the medication causes. When the first-line treatments do not work sufficiently, it is currently unknown what medication works best as a second-line treatment. This study aims to investigate if the first treatment does not work sufficiently, if it is better to use clozapine (generally used as a third-line treatment), instead of the second-line treatment. Third-line treatments are expected to be more effective, and it is expected that the side effects are similar when used as a second-line treatment.
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
23/EM/0266
Date of REC Opinion
13 Mar 2024
REC opinion
Further Information Favourable Opinion